Wells Fargo & Company Plus Therapeutics, Inc. Transaction History

Wells Fargo & Company

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.27 - $0.48 $1 - $1	4 Added 1.74%	234 $0
Q4 2022 Feb 13, 2023	BUY	$0.3 - $0.48 $23 - $37	79 Added 52.32%	230 $0
Q3 2022 Nov 14, 2022	BUY	$0.48 - $1.0 $0 - $1	1 Added 0.67%	151 $0
Q2 2022 Aug 12, 2022	BUY	$0.46 - $1.02 $8 - $19	19 Added 14.5%	150 $0
Q1 2022 May 16, 2022	BUY	$0.87 - $1.32 $30 - $46	35 Added 36.46%	131 $0

Q4 2021 Feb 14, 2022	BUY	$1.03 - $1.94 $21 - $40	21 Added 28.0%	96 $0
Q3 2021 Nov 15, 2021	SELL	$1.83 - $2.46 $113 - $152	-62 Reduced 45.26%	75 $0
Q2 2021 Aug 16, 2021	BUY	$2.0 - $2.89 $154 - $222	77 Added 128.33%	137 $0
Q1 2021 May 13, 2021	BUY	$2.1 - $3.75 $63 - $112	30 Added 100.0%	60 $0
Q4 2020 Feb 09, 2021	BUY	$2.0 - $2.76 $8 - $11	4 Added 15.38%	30 $0
Q1 2020 May 14, 2020	BUY	$1.05 - $2.85 $27 - $74	26 New	26 $0

Ticker PSTV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,601,400
Market Cap $51.4M
Description
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, lep...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.